Assessment of Electrophysiological Effects of 150 mg and 600 mg of Dabigatran Etexilate as Single Dose on the QT Interval in Healthy Female and Male Subjects. A Randomised, Placebo Controlled, Double-blind Three-way Crossover Study With an Open Label Positive Control (Moxifloxacin)
Latest Information Update: 30 Jul 2014
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Bacterial infections; Venous thromboembolism
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharma KG
- 02 May 2011 New trial record
- 05 Apr 2011 Results presented at the 60th Annual Scientific Session of the American College of Cardiology.